Table S

13. 10.0%. 7.8% ƚ . 14. 7.6%. 7.8% . 15. 5.8%. 7.8% ... ƚ Beyond 13 years, there was insufficient sample size within SEER for stable reporting of estimates and a constant annual mortality risk of 7.8% is modeled. Table S2 – KN189. ITC Time varying hazard ratios for OS and PFS, by PD-L1 subgroup, for pembrolizumab monotherapy vs. pembrolizumab + chemotherapy . Month* Subgroup (HR, 95% CI ... ................
................